Kanna's Regulatory Status in the US in 2026

kannaregulatory statusdietary supplementFDA2026legal

Kanna (Sceletium tortuosum) is legal in the United States, unscheduled under the Controlled Substances Act, and sold widely as a dietary supplement. For most consumers, that is the headline. But the regulatory picture has some nuance worth understanding — especially for practitioners who might recommend it, retailers who sell it, or individuals who want to understand what they are actually buying. This post covers kanna’s current regulatory status and the questions that remain open.

Federal Scheduling Status

Kanna and its primary alkaloids — mesembrine, mesembrenone, and related compounds — are not listed as scheduled substances under the federal Controlled Substances Act. The DEA does not currently list kanna among its controlled or monitored substances. This means it is not a controlled substance, and no prescription is required to purchase or possess it.

This status differs from several other plant-derived substances that have faced scheduling pressure. Kratom (Mitragyna speciosa), for example, has been the subject of repeated DEA scheduling actions, though it remains unscheduled federally as of 2026. Kanna has not been the target of comparable regulatory attention.

For current scheduling information on any substance, the DEA’s drug scheduling resource is the authoritative source.

How the FDA Regulates Kanna as a Supplement

Because kanna is sold as a dietary supplement in the US, it falls under the Dietary Supplement Health and Education Act (DSHEA) of 1994. DSHEA established a framework where dietary supplements do not require FDA pre-market approval for safety or efficacy — the manufacturer is responsible for ensuring the product is safe before bringing it to market, and the FDA can take action after the fact if a product is found to be unsafe or mislabeled.

This means kanna products are not required to prove efficacy before sale. A manufacturer can sell kanna capsules without conducting any clinical trials, as long as the product is not falsely labeled and does not make impermissible drug claims.

Permissible claims for dietary supplements include structure/function claims: statements that describe how a nutrient affects normal function (“supports a calm mood,” “promotes relaxation”). These claims do not require FDA approval but must be accompanied by a disclaimer that the FDA has not evaluated the statement and the product is not intended to diagnose, treat, cure, or prevent any disease.

Impermissible claims include disease claims: statements that the product treats, cures, or prevents a specific disease or condition (“treats anxiety disorder,” “prevents depression”). A manufacturer who makes such claims is essentially marketing the product as a drug, which requires FDA approval the product does not have.

This distinction matters for consumers: if you see a kanna product that claims to “treat” a specific diagnosed condition, that claim is likely not FDA-compliant. A product that says it “supports a balanced mood” is operating within the supplement framework.

Import and Supply Chain Considerations

Kanna is primarily grown in South Africa. Products sold in the US market are typically imported, either as raw plant material or as standardized extracts. The FDA has authority over imported dietary supplement ingredients and finished products, and can detain shipments that violate labeling rules or appear to be adulterated.

Standardized extracts — particularly the Zembrin brand — have a more documented supply chain and quality control process than raw dried plant material, which can vary significantly in alkaloid content based on growing conditions, processing method, and fermentation time. For consumers, purchasing from suppliers who provide certificate of analysis (COA) documentation is a reasonable quality check.

Drug Interactions and Labeling Responsibility

One area where kanna’s regulatory status creates real consumer risk is drug interactions. Because kanna appears to act as a serotonin reuptake inhibitor, combining it with prescription SSRIs, SNRIs, MAOIs, or other serotonergic medications may carry risk of additive effects. These interactions are not well-studied in humans, but the theoretical pharmacological basis for concern is reasonable.

DSHEA does not require supplement manufacturers to prominently warn about drug interactions in the same way prescription labels are required to. Some products include general interaction warnings; others do not. This places responsibility on the consumer (or their clinician) to assess interactions before use.

Anyone taking prescription psychiatric medications who is considering adding kanna should discuss it with their prescribing clinician or pharmacist. This is not a formality — it is a real safety consideration.

What Could Change

Regulatory status for supplements can change. If evidence emerged of significant adverse events associated with kanna, the FDA could issue warnings, require reformulation, or initiate action under its safety authorities. If DEA became concerned about abuse potential (which would require a meaningful change in use patterns and evidence), scheduling proceedings could follow. Neither of these scenarios is currently active or anticipated, but no supplement’s legal status should be assumed to be permanent.

Consumers and retailers who want to stay current on supplement regulations can follow the FDA’s dietary supplement guidance page for updates.

The Practical Bottom Line

In 2026, kanna is:

  • Legal to purchase, possess, and use in the US
  • Sold as a dietary supplement, not a medicine
  • Not FDA-evaluated for efficacy or safety (as with all supplements)
  • Imported primarily from South Africa with varying quality standards
  • Subject to restrictions on what health claims can be made about it
  • Potentially interactive with serotonergic medications — discuss with a clinician if that is relevant to you

For questions about kanna as part of a wellness approach, reach out here and we are happy to help.

This content is for educational purposes only and does not constitute medical advice. Consult a licensed clinician about your specific situation.

Drafted by AI and reviewed by our editorial team. Last updated 2026-05-30.